GCM
RLMD icon

Ghisallo Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Ghisallo Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,000
Closed -$338K – 384
2021
Q4 		$338K Buy
+15,000
New +$334K 0.02% 421

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Ghisallo Capital Management's RLMD Position: Q1 2022 in Review

Ghisallo Capital Management sold out of Relmada Therapeutics (RLMD) in Q1 2022, closing a stake of 15,000 shares — an estimated $338K sold.

Ghisallo Capital Management first reported a position in RLMD in Q4 2021 and held it in 1 quarter. The position peaked at $338K in Q4 2021. 113 funds tracked by Wall St. Rank hold RLMD as of Q1 2022.

  • Ghisallo Capital Management reported no remaining Relmada Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Ghisallo Capital Management sold 15,000 Relmada Therapeutics shares in Q1 2022, an estimated $338K.
  • Ghisallo Capital Management first reported a position in Relmada Therapeutics in Q4 2021 and held it in 1 quarter.
  • Ghisallo Capital Management's Relmada Therapeutics position peaked at $338K in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2022.

Based on Ghisallo Capital Management's 13F filing for Q1 2022, filed 10 May 2022.